Clinical trials: Lymphoma
Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
We hope to demonstrate that YESCARTA can be safely administered in the outpatient setting if we closely monitor subjects with physical exams, wearable devices, and telemedicine visits and only admit those who meet specified…
- Trial name
- NCT05108805
- Testing
- Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase II trial studies how well ibrutinib and brentuximab vedotin work in treating patients with Hodgkin lymphoma that has returned (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT02744612
- Testing
- Brentuximab Vedotin, Ibrutinib
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- City of Hope Medical Center
Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
SUBLOCADE Rapid Initiation Extension Study
A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.
- Trial name
- NCT04060654
- Testing
- Sublocade
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Indivior Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Latin American Real-world Study in Acute Leukemia
The objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (R/R) B-cell ALL and de novo AML in 4 Latin…
- Trial name
- LOYAL (NCT05166135)
- Where
- 14 sites in Argentina, Brazil and 2 more
- Volunteers
- 589 people
- Sponsor
- Pfizer
Non-Hodgkin Lymphoma
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
This is an open-label, non-randomized, interventional, single group assignment study of GDA-201, an allogeneic cryopreserved Natural Killer (NK) cell therapy derived from donor peripheral blood, in combination with rituximab…
- Trial name
- NCT05296525
- Testing
- GDA-201
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Gamida Cell ltd
Leukemia, Lymphocytic, Lymphoblastic Lymphoma
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
AINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and lymphoblastic lymphoma (LL).
- Conditions
- Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia
- Trial name
- NCT03792256
- Testing
- Palbociclib, Cytarabine, Methotrexate
- Where
- 19 sites in United States
- Volunteers
- 12 people
- Sponsor
- Children's Oncology Group
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory Epstein-Barr Virus…
- Trial name
- NCT03397706
- Testing
- VRx-3996 and valganciclovir
- Where
- 28 sites in United States, Brazil
- Volunteers
- 64 people
- Sponsor
- Viracta Therapeutics, Inc.
Lymphoma
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in participants with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with…
- Trial name
- (CITADEL-205) (NCT03235544)
- Testing
- Parsaclisib
- Where
- 103 sites in United States, Belgium and 9 more
- Volunteers
- 162 people
- Sponsor
- Incyte Corporation
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or…
- Conditions
- Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- R/R (NCT04419389)
- Testing
- APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Aprea Therapeutics
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
This phase II trial studies how well nivolumab works in treating patients with human T-cell leukemia virus (HTLV)-associated T-cell leukemia/lymphoma.
- Conditions
- Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
- Trial name
- NCT02631746
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Pharmacogenomic Study
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
- Trial name
- CITADEL-203 (NCT03126019)
- Testing
- Parsaclisib
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 126 people
- Sponsor
- Incyte Corporation
Multiple Myeloma, Lymphoma
Ixazomib Rollover Study
The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
- Conditions
- Multiple Myeloma, Lymphoma, Amyloidosis
- Trial name
- NCT02924272
- Testing
- Ixazomib
- Where
- 26 sites in United States, Belgium and 9 more
- Volunteers
- 32 people
- Sponsor
- Takeda
COVID-19 Vaccines, Telemedicine
Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool
This study will determine the effectiveness of a vaccine communication mobile health app on parental decisions to vaccinate their children against coronavirus disease 2019 (COVID-19).
- Conditions
- COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
- Trial name
- MoVeUP (NCT05386355)
- Testing
- COVID-19 Vaccine Uptake App, General Health App
- Where
- 15 sites in United States
- Volunteers
- 1,934 people, healthy volunteers welcome
- Sponsor
- IDeA States Pediatric Clinical Trials Network
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic disease.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma
- Trial name
- NCT00719888
- Testing
- Cyclophosphamide, Cyclosporine, Double-Unit Umbilical Cord Blood Transplantation
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- Fred Hutchinson Cancer Center
Peripheral T-cell Lymphoma
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma…
- Trial name
- PRIMO (NCT03372057)
- Testing
- Duvelisib
- Where
- 36 sites in United States, Germany and 3 more
- Volunteers
- 156 people
- Sponsor
- SecuraBio
Follicular Lymphoma, Endometrial Cancer
Study of Copanlisib and Ketogenic Diet
This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies: (a) relapsed or refractory (R/R)…
- Trial name
- NCT04750941
- Testing
- Copanlisib, Ketogenic Diet
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
This phase II trial studies how well sapanisertib works in treating patients with acute lymphoblastic leukemia that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory).
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT02484430
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
This phase II trial studies how well copanlisib hydrochloride and nivolumab work in treating patients with diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma that has come back (recurrent) or does not…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT03484819
- Testing
- Copanlisib Hydrochloride, Nivolumab
- Where
- 15 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Mantle Cell Lymphoma
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
This study is being done to understand how to treat Mantle Cell Lymphoma (MCL). The goals of treatment are to control the lymphoma with the least amount of side effects.
- Trial name
- NCT01437709
- Testing
- Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center